Detalhe da pesquisa
1.
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Cancer
; 121(19): 3481-90, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26177599
2.
Drug interactions and the pharmacist: focus on everolimus.
Ann Pharmacother
; 47(7-8): 1055-63, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23757385
3.
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Clin Cancer Res
; 23(21): 6400-6410, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28790114
4.
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
J Clin Oncol
; 33(9): 1060-6, 2015 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605849